Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the LD 500 investor conference on September 2, 2020, at 9:40 AM ET. CEO Ofer Haviv will present to a live audience, highlighting Evogene's innovations in computational biology aimed at enhancing life-science product development across agriculture and health sectors. The LD 500, which runs from September 1-4, is fully virtual, allowing broad accessibility for investors. Interested parties can register online to participate in the conference and meet the CEO.
Evogene Ltd. (NASDAQ: EVGN) reported its Q2 2020 financial results, highlighting a cash position of approximately $38.1 million and revenues of $0.3 million, up from $0.2 million YoY. R&D expenses rose to $3.9 million, compared to $3.5 million in Q2 2019. Despite the COVID-19 challenges, the company aims to advance its technology solutions in agriculture and human health, with key projects in herbicides and microbiome-based therapeutics. Operating loss increased to $5.2 million from $4.7 million in the previous year, while the net loss reached approximately $4.8 million, compared to $4.1 million YoY.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual 2020 Industrials Conference on August 6, 2020, at 8:00 am EST. The presentation will highlight the company's innovative Computational Predictive Biology (CPB) platform, focusing on ag-chemicals and ag-biologicals. Investors interested in a meeting can contact Evogene's Investor Relations team. Evogene is dedicated to enhancing life-science product development through its unique technology and aims to address various market segments, including agriculture and human health.
Evogene Ltd. (NASDAQ: EVGN) will release its second-quarter 2020 financial results on August 5, 2020. The company's management will discuss these results in a conference call at 09:00 AM ET and 16:00 Israel time. The call can be accessed via telephone or live webcast on their website. Evogene focuses on computational biology to develop life-science products and employs its Computational Predictive Biology platform across various sectors including human health and agriculture.